<DOC>
	<DOCNO>NCT00649896</DOCNO>
	<brief_summary>The primary objective study compare adhesive quality new formulation Mylan Estradiol Transdermal System Climara® Transdermal System follow single system application 80 healthy postmenopausal female volunteer . As secondary objective , primary dermal irritation assess removal transdermal system .</brief_summary>
	<brief_title>Evaluation Adhesion Quality New Formulation Mylan Estradiol Transdermal System 0.025 mg/Day Climara® Transdermal System 0.025 mg/Day</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Age : 4069 year . 2 . Sex : Females . 3 . Weight : At least 52 kg ( 115 lb ) within 30 % Ideal Body Weight ( IBW ) , reference Table `` Desirable Weights Adults '' Metropolitan Life Insurance Company , 1999 ( See Part II : ADMINISTRATIVE ASPECTS OF HUMAN BIOAVAILABILITY PROTOCOLS ) . 4 . Absence menses one year postmenopausal subject , least 6 week oophorectomized subject . ( For oophorectomized subject , operative report document bilateral oophorectomy surgical pathology report document absence malignant disease . ) 5 . Baseline FSH 17betaestradiol serum level consistent postmenopausal status confirm within 14 day initiation study medication . ( FSH great equal 40 mIU/mL ; 17betaestradiol less equal 31 pg/mL ) 6 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation 12lead ECG ) perform within 14 day initial patch application . 7 . The physical examination shall include pelvic breast exam . a. Pelvic finding consistent hypoestrogenemia . b . A mammogram require perform within last 12 month . c. A Papanicolaou ( `` Pap '' ) smear require subject intact uterus cervix perform within last 6 month . 1 . Institutionalized subject use . 2 . Social Habits : . Use tobacco product . b. Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . c. Ingestion vitamin within 48 hour prior initial dose study medication . d. Any recent , significant change dietary exercise habit . 3 . Medications : 1 . Use medication within 14 day prior initial dose study medication . 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 3 . Use systemic antibiotic , estrogen , hormone within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant chronic disease ( limited ) : 1 . Thrombotic disorder . 2 . Coronary artery cerebrovascular disease . 3 . Liver , kidney gallbladder dysfunction/disorder ( ) . 4 . Fibrocystic disease breast nodule . 5 . Family history breast cancer . 6 . Diabetes endocrinological disease . 7 . Estrogendependent neoplasia . 8 . Postmenopausal uterine bleeding . 9 . Endometrial hyperplasia . b . History drug and/or alcohol abuse . c. Acute illness time either prestudy medical evaluation dosing . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II : ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Subjects receive investigational drug within 30 day prior initial dose study medication . 7 . Allergy hypersensitivity tape adhesive ( ex . Bandaids , medical tape ) , estradiol hormonal product .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>